VELETRI Market Report 2026

VELETRI Market Overview

• VELETRI market size has reached to $1.45 billion in 2025 • Expected to grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Rising Prevalence Of Venous Diseases Fuels Market Growth • Market Trend: Generic Veletri Launches Expand Access and Affordability in Pulmonary Arterial Hypertension Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under VELETRI Market?

VELETRI (epoprostenol) is a prostacyclin vasodilator used to treat pulmonary arterial hypertension (PAH). It helps lower blood pressure in the lungs by relaxing blood vessels and improving blood flow. Unlike Flolan, VELETRI does not require refrigeration, making it more convenient for continuous infusion. It is administered intravenously to improve exercise capacity and symptoms in PAH patients. The main product types of VELETRI are injectable and inhalation. Veletri injectable is a prostacyclin (epoprostenol) therapy used for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms. Various applications include pulmonary arterial hypertension and others, and these products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The VELETRI Market Growth Forecast?

The veletri market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing pah prevalence, growth in specialty pah centers, rising demand for stable formulations, expansion of infusion therapy adoption, increased awareness of pah. Major trends in the forecast period include growing adoption of non-refrigerated prostacyclin therapies, increased use of continuous infusion pah treatments, rising demand for advanced pah vasodilators, expansion of hospital-based pah management, increased focus on improving pah patient mobility.

Global VELETRI Market Segmentation

1) By Formulation Stability Type: Room-Temperature Stable Formulation, Refrigeration-Required Formulation 2) By Treatment Setting: Hospitals, Specialized Pulmonary Hypertension Centers 3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies Subsegments: 1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation, Extended Stability Infusion Solution 2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation, Limited-Stability Infusion Solution

What Are The Drivers Of The VELETRI Market?

The increasing prevalence of venous diseases is expected to propel the growth of the VELETRI market going forward. Venous diseases are conditions where the veins have impaired blood flow, causing swelling, pain, and possible complications like varicose veins and deep vein thrombosis. The increasing prevalence of venous diseases is driven by factors such as an aging population, sedentary lifestyles, obesity, and improved diagnostic capabilities. Veletri is used to improve exercise capacity and reduce symptoms in patients with venous diseases affecting the pulmonary vasculature. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government organization, each year, up to 900,000 individuals in the United States are impacted by venous thromboembolism (VTE), a condition characterized by blood clots, with an estimated 60,000 to 100,000 fatalities attributed to VTE annually. Therefore, the increasing prevalence of venous diseases is driving the growth of the VELETRI industry. The rising healthcare expenditure is expected to propel the growth of the VELETRI market going forward. Healthcare expenditure refers to the total financial resources spent on medical goods and services to maintain and improve population health. Healthcare expenditure is rising as an aging population requires more frequent medical care and long-term health services. Higher healthcare expenditure supports greater use of VELETRI by improving access to specialized PAH care, expanding reimbursement for high-cost therapies, and strengthening the clinical infrastructure needed to deliver continuous IV treatment. For instance, in April 2025, according to the Office for National Statistics, a UK-based government department, between 2023 and 2024, total healthcare spending increased by 6.5% in nominal terms, and by 2.4% in real terms after accounting for inflation. Therefore, the rising healthcare expenditure driving the growth of the VELETRI industry.

Key Players In The Global VELETRI Market

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

Global VELETRI Market Trends and Insights

Major companies operating in the Veletri market are focusing on expanding access via generic formulations, such as FDA-approved epoprostenol sodium injection, to provide cost-effective treatment options for pulmonary arterial hypertension patients. Generic Veletri refers to therapeutically equivalent versions of the branded epoprostenol product that meet FDA standards for quality, safety, and efficacy, offering the same clinical benefits at a lower cost. For instance, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for its generic Veletri (epoprostenol sodium) injection. The product is supplied in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and provides the same prostacyclin mimetic activity as the branded version, helping improve exercise tolerance and manage symptoms in PAH patients.

Regional Insights

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the VELETRI Market?

The VELETRI market consists of sales of injections, biosimilars, infusion systems, and related equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the VELETRI Market Report 2026?

The veletri market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the veletri industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.